Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We would like to congratulate Tariq Khoyratty, who has been appointed as a Celgene Fellow to study the link between neutrophil chromatin organisation in rheumatic patients and their ability to form pathogenic extracellular traps.

Recent evidence suggests an essential contribution of neutrophils in immunity, inflammation and cancer that extend far beyond their well-known anti-microbial responses. This evidence includes their ability to release extracellular DNA structures. The release of extracellular DNA leads to externalizing enhanced levels of putative autoantigens, and is considered to be particularly relevant to neutrophil deleterious roles in rheumatic diseases. This phenomenon is currently collectively referred to as neutrophil extracellular trap (NET) formation.

PAD4 is an enzyme capable of citrullinating proteins that is being considered as an interesting therapeutic target in rheumatic disorders. The primary interest is to determine whether PAD4 inhibition impacts NET formation in human neutrophils in response to disease-relevant stimuli and to determine whether sub-populations of patients are more prone to citrullination-associated NETosis and thus more likely to respond to a PAD4 inhibitor. Mechanistically, NET formation has been linked to a programmed genome disassembly that is precisely organised and sequence programmed at the level of chromatin organisation.

Speaking of the award, Tariq commented “Ultimately, our aim is to define an early signature in peripheral neutrophils that would correlate with disease severity and propensity to form NETs and can easily be detected in human serum or blood.”

Tariq will be based primarily in the Kennedy Institute and work under the supervision of Prof Irina Udalova and Raashid Luqmani

The fellowship starts in November 2017 and runs for 36 months.

Similar stories

Major ERC funding awarded to Professor Michael Dustin

Funding General

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

Professor Michael Dustin elected to the National Academy of Sciences

Awards

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

NDORMS researchers awarded for Dupuytren research

Awards

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards Funding

Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.